For the quarter ending 2025-09-30, BTMD had $8,447K increase in cash & cash equivalents over the period. $13,573K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 9,216 | 19,764 |
| Depreciation and amortization | 952 | 1,767 |
| Bad debt expense | 624 | 962 |
| Amortization of debt issuance costs | 206 | 412 |
| Provision for obsolete inventory | -169 | 1,100 |
| Non-cash lease expense | 137 | 268 |
| Non-cash interest on share repurchase liability | 742 | 1,986 |
| Share-based compensation expense | 2,410 | 4,313 |
| (gain) loss from change in fair value of earnout liabilities | -2,920 | -8,856 |
| Deferred income taxes | -246 | 1,285 |
| Accounts receivable | -479 | 2,406 |
| Inventory | 4,145 | -1,613 |
| Other assets | -4,039 | 2,387 |
| Accounts payable | 496 | -1,950 |
| Deferred revenue | -56 | -60 |
| Accrued expenses | 2,439 | -3,910 |
| Payments pursuant to tra | 0 | 93 |
| Operating lease liabilities | -132 | -255 |
| Net cash provided by operating activities | 14,072 | 13,553 |
| Purchases of property and equipment | 499 | 3,439 |
| Purchases of capitalized software | 191 | 371 |
| Net cash used in investing activities | -690 | -3,810 |
| Repurchases of class a common stock | 3,365 | - |
| Principal repayments on term loan | 1,562 | 3,125 |
| Payments on repurchase liability | 0 | 25,081 |
| Proceeds from exercise of stock options | 0 | 226 |
| Issuance of stock under purchase plan | 0 | 72 |
| Distributions | 8 | 1,581 |
| Net cash used in financing activities | -4,935 | -29,489 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 5 |
| Net decrease in cash and cash equivalents | 8,447 | -19,741 |
| Cash and cash equivalents at beginning of period | 39,342 | - |
| Cash and cash equivalents at end of period | 28,048 | - |
biote Corp. (BTMD)
biote Corp. (BTMD)